2022 American Transplant Congress
Association Between Time in Therapeutic Range for Warfarin and Time in Therapeutic Range for Calcineurin Inhibitors in Patients That Received Left Ventricular Assist Devices as Bridge to Transplant
1Baylor St. Luke's Medical Center, Houston, TX, 2Baylor College of Medicine, Houston, TX
*Purpose: Medication nonadherence is a leading cause of avoidable graft failure post-transplant. The relationship between medication adherence in patients with left ventricular assist devices (LVADs)…2021 American Transplant Congress
Waitlist and Post-Transplant Outcomes of Candidates With Lvad: Comparison of Old and New Heart Allocation Policies
*Purpose: The new heart allocation policy took effect in October 2018. Its risk stratification scheme prioritizes patients with short-term devices, raising concern that candidates with…2021 American Transplant Congress
Waitlist and Post-Transplant Outcomes of Candidates with Iabp or Ecmo: Comparison of Old and New Heart Allocation Policies
*Purpose: New heart allocation policy prioritizes candidates on short-term circulatory support to promote transplant of the sickest candidates. There has been a shift in the…2021 American Transplant Congress
Clinical Features and Outcomes of Candidemia in Patients with Left Ventricular Assist Devices
Infectious Diseases, Washington University School of Medicine, St Louis, MO
*Purpose: Fungal infections represent an uncommon etiology of Left Ventricular Assist Device (LVAD) infections but can lead to significant morbidity and mortality. In this study,…2020 American Transplant Congress
Multiplicity of Non-HLA Targets for Antibodies Developed in Association with Ventricular Assist Device Implantation
Baylor University Medical Center and Baylor Scott & White Research Institute, Dallas, TX
*Purpose: Multiple non-HLA antibodies have been implicated in poor outcomes after heart transplantation. Development of HLA and Non-HLA antibodies have been reported in association with…2020 American Transplant Congress
Possible Mechanism of Sensitization against Angiotensin Type II Receptor after LVAD Implantation
1Surgery, VCUHS, Richmond, VA, 2Cardiology, VCUHS, Richmond, VA
*Purpose: Detection of antibody (Ab) against angiotensin-II receptor (AT1R) following VAD implantation portends poorer outcomes for heart transplantation (HT). However, the cause of this sensitization…2020 American Transplant Congress
Effect of Intravenous Ferric Gluconate on Post Heart Transplant Outcomes in Patients Bridged with Left Ventricular Assist Devices
Internal Medicine, Loyola University Medical Center, Maywood, IL
*Purpose: Our study examined the effect of intravenous (IV) ferric gluconate compared to oral iron repletion in reducing 30-day hospital readmissions and all-cause mortality in…2020 American Transplant Congress
Management and Outcomes of Heart Transplant Recipients with Pre-Transplant Left Ventricular Assist Device Infections
Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN
*Purpose: Infection involving Left Ventricular Assist Device (LVAD) in patients who receive device therapy as a bridge to heart transplantation (HT) is a serious complication.…2020 American Transplant Congress
Characteristics and Outcomes of Patients with Cystic Fibrosis Receiving Lung Transplant with and without ECMO Bridge – A Single Center Experience
Pulmonary & Critical Care, USC, Los Angeles, CA
*Purpose: ECMO is a viable bridge to lung transplantation (LTx) for end-stage cystic fibrosis (CF) patients refractory to traditional medical support. We sought to identify…2019 American Transplant Congress
Efficacy of Long-Acting Octreotide in Left Ventricular Assist Device Patients with Recurrent Gastrointestinal Bleeding
*Purpose: Continuous flow ventricular assist device (VAD) patients have a high risk of recurrent gastrointestinal bleeding, often leading to readmission and morbidity. Intramuscular long-acting octreotide…
American Transplant Congress abstracts